Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study

Grants

Funding Acknowledgements

This work was supported by Cancer Research UK grants C12292/A20861 and C12292/A11174.r This work was partially supported by the Spanish Ministry of Economy and Competitiveness (SAF201457680-R) and the Spanish Centre for Biomedical Network Research on Rare Diseases. This work was partially supported by Chancellors Distinguished Chair in Biomedical Sciences Professorship. FPGMX grant number FISPI05/2275 and by the Mutua Madrilen~ a Foundation (FMMA).r Part of this work was supported by the Canadian Institutes of Health Research for the "CIHR Team in Familial Risks of Breast Cancer" program (grant number CRN87521) and the Ministry of Economic Development, Innovation and Export Trade (grant number PSR-SIIRI701). The PERSPECTIVE project was supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research (GPH-129344), the Ministe` re de l'E ' conomie, de la Science et de l'Innovation du Que ' bec through Genome Que ' bec, and the Quebec Breast Cancer Foundation.r This study was supported by the German Cancer Research Center.r EMBRACE is supported by Cancer Research UK grants C1287/A10118 and C1287/A11990. D.G. E. is supported by a National Institute for Health Research (NIHR) grant through the Biomedical Research Centre, Manchester (IS-BRC-1215-20007). The investigators at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust are supported by an NIHR grant through the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. R.E. and E. B. are supported by a Cancer Research UK grant C5047/A8385. R.E. is also supported by the NIHR through the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. A.C.A. is funded by Cancer Research UK grants C12292/A20861, C12292/A11174.r The German Consortium of Hereditary Breast and Ovarian Cancer is supported by the German Cancer Aid (grant number 110837; R.K.S.). This work was supported by LIFE e Leipzig Research Center for Civilization Diseases, Universitat Leipzig. LIFE is funded by means of the European Union, by the European Regional Development Fund, and by means of the Free State of Saxony within the framework of the excellence initiative.r The national French cohort, GENEPSO, had been supported by a grant from the Fondation de France and by grants from the Ligue Nationale Contre le Cancer and is being supported by a grant from Institute National du Cancer as part of the European program ERA-NET on Translational Cancer Research (TRANSCAN-JTC2012, n2014-008).r The Health Care Service Corporation was supported by a grant RD12/0036/0006 and 15/00059 from Instituto de Salud Carlos III (Spain), partially supported by European Regional Development FEDER funds.r The HEBON study is supported by the Dutch Cancer Society grants NKI1998-1854, NKI2004-3088, and NKI2007-3756; the Netherlands Organisation of Scientific Research grant NWO 91109024; the Pink Ribbon grants 110005 and 2014-187.WO76; the Biobanking and BioMolecular Resources Research Infrastructure grant NWO 184.021.007/CP46; and the TRANSCAN grant JTC 2012 Cancer 12-054.r The International Hereditary Cancer Centre was supported by grant number PBZ_KBN_122/P05/2004 and by the National Center for Research and Development (NCBR) within the framework of the international ERA-NET TRANSAN JTC 2012 application number Cancer 12-054 (contract number ERA-NET-TRANSCAN/07/ 2014).r MODSQUAD e Czech Republic, Brno, was supported by MH CZ e DRO (MMCI, 00209805).r The Hungarian Breast and Ovarian Cancer Study was supported by Hungarian research grants KTIA-OTKA CK-80745 and NKFI OTKA K-112228 and by the Norwegian EEA Financial Mechanism HU0115/NA/2008-3/O P9.r Lund-BRCA collaborators are supported by the Swedish Cancer Society, Lund Hospital Funds, and European Research Council advanced grant ERC-2011-294576. Stockholm-BRCA collaborators are supported by the Swedish Cancer Society.r This study was presented as a poster at the 7th International Symposium of the Hereditary Breast and Ovarian Cancer Foundation and the McGill Program in Cancer Genetics, Montreal, Que ' bec, Canada, May 8e11, 2018.